AdaptVac ApS: Financial statements 2020
CVR: 38732730
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
AdaptVac ApS (CVR 38732730) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK 20,231,326 and a net result of DKK 15,460,206 compared with DKK -185,145 the year before. That is an increase of 1,327.6% compared with the year before. Equity in the 2020 report amounted to DKK 15,338,579. The solvency ratio was 39.7%. The company had 3 employees in the financial year.
- Gross Profit
- DKK 20,231,326
- Profit/Loss
- DKK 15,460,206
- Equity
- DKK 15,338,579
- Total Assets
- DKK 38,629,652
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | 20.2 mio. | 15.5 mio. | 15.3 mio. | 3 |
| 2019 | - | 1.4 mio. | -185 t. | -122 t. | 3 |
| 2018 | - | 432 t. | 334 t. | 64 t. | 0 |
Official annual report
How creditworthy is AdaptVac ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
AdaptVac ApS has published its annual report for 2019. Gross profit came to DKK 1,417,122, and the net result was DKK -185,145.
As of February 26, 2020, Willem Adriaan De Jongh has left the board of directors of AdaptVac ApS.
As of January 6, 2020, Allan Rosetzsky has joined the board of directors of AdaptVac ApS.
As of January 6, 2020, Morten Agertoug Nielsen has joined the board of directors of AdaptVac ApS.
As of January 6, 2020, Steen Søren Klysner has left the board of directors of AdaptVac ApS.
As of January 5, 2020, Morten Agertoug Nielsen has left the board of directors of AdaptVac ApS.
About AdaptVac ApS
AdaptVac ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Willem Adriaan De Jongh and Adam Frederik Sander Bertelsen. The board consists of Morten Agertoug Nielsen (chair), Adam Frederik Sander Bertelsen, Ali El-Salanti and Jacob Hjulmand. The company is owned by EXPRES2ION BIOTECHNOLOGIES ApS and NextGen Vaccines Holding ApS. According to the 2025 annual report, the company had an average of 7 employees. In 2025, the company reported a gross profit of DKK -3,160,505 and a net result of DKK -7,053,665 compared with DKK 1,714,349 the year before. Equity in the 2025 report amounted to DKK 10,808,696.